ALung Technologies brings in $2.6m
Artificial lung-like device developer ALung Technologies has raised $2.6 million in a new round of financing, according to an SEC filing posted this week. Pittsburgh-based ALung’s Hemolung device is an extracorporeal carbon dioxide removal system that works by removing carbon dioxide and delivering oxygen directly to a patient’s blood via a small catheter inserted into the jugular or femoral vein. Money in the round so far has come from 36 anonymous investors, with the company seeking another $1.4 million before closing the debt and option round, according to the SEC filing. The company has not yet stated how it intends to use funds raised in the round. Last January, ALung Technologies reported raising $10.8 million in a round of debt financing. A month earlier, the company said its Hemolung RAS extracorporeal carbon dioxide removal device was selected for use in the world’s 1st pivotal trial of ECCO2R technology used to treat patients with acute respiratory failure. The U.K.’s National Institute for Health Research will supply $3.1 million (GBP £2.1 million) in funding for the 1,120 patient Rest trial, which looks to examine the effect of protective ventilation with veno-venous lung assist devices during respiratory failure. The trial will be jointly led by Queen’s University and Belfast Health and Social Services Trust, the company said. The post ALung Technologies brings in $2.6m appeared first on MassDevice.
Conclusions: In patients with FIP, PVR is a significant contributor of 6MWD, independently from the extent of fibrosis on HRCT. These results strengthen both the rationale to use 6MWD as endpoint in FIP and to target APH with specific therapies.Respiration
ConclusionsThe trajectory of physical HRQOL in patients receiving SLT declines over time compared to DLT indicating that, in the longer-term, SLT recipients are more likely to have physical HRQOL scores that fall substantively below general population norms. Physical HRQOL after five years may be a consideration for lung allocation and patient counseling regarding expectations when recommending SLT or DLT.
Authors: Tissot A, Foureau A, Brosseau C, Danger R, Roux A, Bernasconi E, Gomez C, Durand M, Picard BR, Le Pavec J, Claustre J, Lacoste P, Benmerad M, Pain M, Siroux V, Royer PJ, Mordant P, Reynaud-Gaubert M, Kessler R, Brugière O, Mornex JF, Dromer C, Dahan M, Knoop C, Boussaud V, Koutsokera A, Botturi-Cavaillès K, Durand E, Loy J, Nicod L, Pison C, Brouard S, Blanc FX, Magnan A, consortium COLT PMID: 30100530 [PubMed - as supplied by publisher]
AbstractComplications following lung transplantation may impede allograft function and threaten patient survival. The five main complications after lung transplantation are primary graft dysfunction, post-surgical complications, alloimmune responses, infections, and malignancy.Primary graft dysfunction, a transient ischemic/reperfusion injury, appears as a pulmonary edema in almost every patient during the first three days post-surgery.Post-surgical dysfunction could be depicted on computed tomography (CT), such as bronchial anastomosis dehiscence, bronchial stenosis and bronchomalacia, pulmonary artery stenosis, and size ...
Jack Palmer, of Kansas City, Missouri, became the 20th infant under a year old to undergo a heart-lung transplant after he was born in January with a congenital heart defect.
American Journal of Transplantation,Volume 0, Issue ja, -Not available-.
We report that the disruption of excitation-contraction coupling contributes to impaired force generation in the mouse model of Sod1 deficiency. Briefly, we found a significant reduction in sarcoplasmic reticulum Ca2+ ATPase (SERCA) activity as well as reduced expression of proteins involved in calcium release and force generation. Another potential factor involved in EC uncoupling in Sod1-/- mice is oxidative damage to proteins involved in the contractile response. In summary, this study provides strong support for the coupling between increased oxidative stress and disruption of cellular excitation contraction mac...
CONCLUSIONS: Exogenous p51A gene can increase its expression in A549 and NCI-H1299 cells, suppress cell growth and induce cell apoptosis. Moreover, it can also cooperate with chemotherapy and reduce the dose and side-effect. p51A gene can suppress tumours in spite of p53 status and p21 gene might be involved. It might become a new promising therapeutic gene of tumours, which will make up for the limitation of p53 gene therapy. PMID: 30095026 [PubMed - as supplied by publisher]
The objective of this review is to present insights into pharmacotherapeutic techniques, which can be used for transdermal delivery of anticancer agents through skin due to its potential to create a new frontier in treatment of cancer. PMID: 30095010 [PubMed - as supplied by publisher]
With the development of medical technology, transplantation has prevailed and become an important tool in the treatment of disease. According to the WHO ’s statistics, as of 2015, approximately 120000 cases of solid organ transplantation have been performed globally. Renal transplantation is the most common, followed by liver transplantation, heart transplantation, lung transplantation, hematopoietic stem cell transplantation, etc. . And, in re cipients of transplantation, seizures usually occur during the postoperative period [2,3].